Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH

Journal of Hepatology

Volumn 50, Issue 4, 2009, Pages 789-796

  Caballero, Francisco ^a   Fernández, Anna ^a   De Lacy, Antonio M ^a   Fernández Checa, Jose C ^a,b   Caballería, Juan ^a   García Ruiz, Carmen ^a  

^a Liver Unit   (Spain)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cholesterol; Mitochondria; NASH; Oxidative stress; Steatohepatitis

Indexed keywords

ABC TRANSPORTER G1; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; FATTY ACID SYNTHASE; FILIPIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; STEROIDOGENIC ACUTE REGULATORY PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FATTY LIVER; FEMALE; HISTOLOGY; HUMAN; LIPID STORAGE; LIVER FIBROSIS; MALE; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STAINING;

ADULT; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; DIABETES COMPLICATIONS; DNA PRIMERS; FATTY LIVER; FEMALE; FILIPIN; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; OBESITY, MORBID; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

EID: 61849095626     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.12.016     Document Type: Article

References (37)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Feldstein A.E., and Gores G.J. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 10 (2005) 3093-3099
3. Tilg H., and Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343 (2000) 1467-1476
4. Day C.P., and James O.F. Steatohepatitis: a tale of two 'hits'?. Gastroenterology 114 (1998) 842-845
5. Koteish A., and Diehl A.M. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16 (2002) 679-690
6. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 (2003) 437-443
7. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34 (2001) 1158-1163
8. Hotamisligil G.S. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 245 (1999) 621-625
9. Ribeiro P.S., Cortez-Pinto H., Sola S., Castro R.E., Ramalho R.M., Baptista A., et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 99 (2004) 1708-1717
10. Tomita K., Tamiya G., Ando S., Ohsumi K., Chiyo T., Mizutani A., et al. Tumour necrosis factor a signaling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55 (2006) 415-424
11. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
12. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
13. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002) 1125-1131
14. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 9 (2008) 125-138
15. Repa J.J., Turley S.D., Lobaccaro J.A., Medina J., Li L., Lustig K., et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289 (2000) 1524-1529
16. Maxfield F.R., and Tabas I. Role of cholesterol and lipid organization in disease. Nature 438 (2005) 612-621
17. Mari M., Caballero F., Colell A., Morales A., Caballeria J., Fernandez A., et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4 (2006) 185-198
18. Puri P., Baille R.A., Wiest M.M., Mirshahi F., Choudhury J., Cheung O., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46 (2007) 1081-1090
19. Matsuzawa N., Takamura T., Kurita S., Misu H., Ota T., Ando H., et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46 (2007) 1392-1403
20. Mari M., Colell A., Morales A., Caballero F., Moles A., Fernandez A., et al. Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-κB activation. Gastroenterology 134 (2008) 1507-1520
21. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., and Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474
22. Kleiner D.E., Brunt E.M., Van Natta M., Belhing C., Contos M.J., Cummings O.W., et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
23. Norman A.W., Dermei R.A., de Kruyff B., and van Deenen L.L. Studies on the biological properties of polyene antibiotics. Evidence for the direct interaction of filipin with cholesterol. J Biol Chem 247 (1972) 1918-1929
24. Feng B., Yao P.M., Li Y., Devlin C.M., Zhang D., Harding H.P., et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 5 (2003) 781-792
25. Hall E.A., Ren S., Hylemon P.B., Rodriguez-Agudo D., Redford K., Marques D., et al. Detection of the steroidogenic acute regulatory protein, StAR, in human liver cells. Biochim Biophys Acta 1733 (2005) 111-119
26. Garcia-Ruiz C., Mari M., Colell A., Morales A., Caballero F., Montero J., et al. Mitochondrial cholesterol in health and disease. Histol Histopathol 24 (2009) 117-132
27. Wouters K., van Gorp P., Biegh V., Gijbels M.J., Duimel H., Lütjohann D., et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic Mouse models of NASH. Hepatology 48 (2008) 474-486
28. Monetti M., Levin M., Watt M.J., Sajan M.P., Marmor S., Hubbard B.K., et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 6 (2007) 69-78
29. Postic C., and Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118 (2008) 829-838
30. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., and Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115 (2005) 1343-1351
31. Montero J., Morales A., Llacuna L., Lluis J.M., Terrones O., Basañez G., et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res 68 (2008) 5246-5256
32. Bose M., Whittal R.M., Miller W.L., and Bose H.S. Steroidogenic activity of StAR requires contact with mitochondrial VDAC1 and phosphate carrier protein. J Biol Chem 283 (2008) 8837-8874
33. Sever N., Yang T., Brown M.S., Goldstein J.L., and DeBose-Boyd R.A. Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Mol Cell 11 (2003) 25-33
34. Song B.L., Javitt N.B., and DeBoyse-Boyd R.A. Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell Metab 1 (2005) 179-189
35. Kiyici M., Gulten M., Gurel S., Nak S.G., Dolar E., Savci G., et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 17 (2003) 713-718
36. Rallidis L.S., Drakoulis C.K., and Parasi A.S. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 174 (2004) 193-196
37. Lewis J.H., Mortensen M.E., Zweig S., Fusco M.J., Medoff J.R., and Belder R. Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46 (2007) 1453-1463